Regulatory Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug BioSpaceThe FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.Rare DiseaseRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) BioSpace The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency. Rare Disease Read full story Post navigation Previous: Bayer’s asundexian starts EU review for ischaemic strokeNext: Lilly wins new FDA approval for eczema drug Ebglyss Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026